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Background. Early-onset group B streptococcal disease (EOGBS) occurs in neonates (days 0–6) born to pregnant women who 
are rectovaginally colonized with group B Streptococcus (GBS), but the risk of EOGBS from vertical transmission has not been sys-
tematically reviewed. This article, the seventh in a series on the burden of GBS disease, aims to estimate this risk and how it varies 
with coverage of intrapartum antibiotic prophylaxis (IAP), used to reduce the incidence of EOGBS.
Methods. We conducted systematic reviews (Pubmed/Medline, Embase, Latin American and Caribbean Health Sciences 
Literature (LILACS), World Health Organization Library Information System [WHOLIS], and Scopus) and sought unpublished 
data from investigator groups on maternal GBS colonization and neonatal outcomes. We included articles with ≥200 GBS colonized 
pregnant women that reported IAP coverage. We did meta-analyses to determine pooled estimates of risk of EOGBS, and examined 
the association in risk of EOGBS with IAP coverage.
Results. We identified 30 articles including 20 328 GBS-colonized pregnant women for inclusion. The risk of EOGBS in settings 
without an IAP policy was 1.1% (95% confidence interval [CI], .6%–1.5%). As IAP increased, the risk of EOGBS decreased, with a 
linear association. Based on linear regression, the risk of EOGBS in settings with 80% IAP coverage was predicted to be 0.3% (95% 
CI, 0–.9).
Conclusions. The risk of EOGBS among GBS-colonized pregnant women, from this first systematic review, is consistent with 
previous estimates from single studies (1%–2%). Increasing IAP coverage was linearly associated with decreased risk of EOGBS 
disease.
Keywords. group B Streptococcus; Streptococcus agalactiae; vertical transmission; risk; neonatal sepsis. 
Maternal colonization with group B Streptococcus (GBS; 
Streptococcus agalactiae) is the most important risk factor for 
early-onset (0–6 days) invasive neonatal GBS disease (EOGBS). 
However, the risk of EOGBS in newborns born to GBS-colonized 
pregnant women has not previously been systematically reviewed 
and quantified. The first and most frequently referenced study is 
from 1973, where 1 infant among 46 pregnant women with vagi-
nal GBS colonization developed EOGBS [1]—that is, around 2% 
risk. However, this was before intrapartum antibiotic prophylaxis 
(IAP) became established in high-income contexts.
Since the 1970s and 1980s [1–8], several observational stud-
ies and randomized controlled trials have demonstrated that 
IAP reduces the risk of EOGBS [9–17], using either microbi-
ological screening (rectovaginal colonization) [16, 18] or clini-
cal risk factors for EOGBS, such as preterm labor (<37 weeks), 
prolonged rupture of membranes (PROM) (>18 hours), mater-
nal fever (≥38.0°C [100.4°F]), or suspicion of chorioamnionitis 
[18–21]. The risk of EOGBS disease may therefore vary, accord-
ing to maternal GBS colonization prevalence, IAP policy, and 
effectiveness of IAP implementation.
This article, assessing the risk of neonatal disease in pregnant 
women colonized with GBS, is part of a supplement estimat-
ing the burden of GBS disease in pregnant women, stillbirths, 
and infants, which is important in terms of public health policy, 
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particularly vaccine development (Figure  1), as outlined else-
where [22]. The supplement includes systematic reviews and 
meta-analyses on GBS colonization and maternal and birth 
adverse outcomes associated with GBS [23–30], which form 
input parameters to a compartmental model to estimate the 
global burden of GBS [31].
The specific objectives of this paper are as follows:
1. To provide a comprehensive and systematic literature review 
and meta-analyses to assess the following parameters: (i) 
risk of EOGBS in settings without an IAP policy, (ii) risk 
of EOGBS at varying levels of IAP implementation (using a 
microbiological screening policy);
2. To assess the data for possible use for estimating the burden 
of EOGBS disease;
3. To evaluate the gaps in the data and recommend what should 
be done to improve the data on risk of EOGBS.
METHODS
This article is part of a protocol entitled “Systematic estimates 
of the global burden of GBS in pregnant women, stillbirths and 
infants,” submitted for ethical approval to the London School 
of Hygiene & Tropical Medicine (reference number 11966) and 
approved on 30 November 2016.
Definitions
Maternal GBS colonization was defined as isolation by culture 
of GBS from either the vagina (high or low), rectum, or perianal 
region during pregnancy. EOGBS was defined as GBS disease 
confirmed by microbiological culture of blood or cerebrospi-
nal fluid (CSF) taken on days 0–6 [28]. We assumed that blood 
or CSF samples were obtained for a clinical indication. We 
excluded cases of “probable” GBS sepsis, where clinical or lab-
oratory signs of infection were accompanied only by neonatal 
GBS colonization, and cases of clinically suspected pneumonia 
with GBS detected in tracheal aspirates, or urinary tract infec-
tions. Intrapartum antibiotic prophylaxis (IAP) was defined as 
intravenous antibiotics given at any time during labor for the 
prevention of EOGBS in GBS-colonized pregnant women. 
Coverage of IAP refers to the proportion of women who 
received IAP, regardless of the timing of administration. Studies 
were categorized as having a policy of IAP for GBS colonization 
if they aimed to provide IAP to all colonized pregnant women 
regardless of risk factors.
Figure 1. Risk of early onset neonatal disease in the disease schema for group B Streptococcus, as described by Lawn et al [22]. Abbreviations: GBS, group B Streptococcus; 
NE, neonatal encephalopathy.
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Data Searches and Inputs
We identified data through systematic review of the published 
literature and through development of an investigator group of 
clinicians, researchers, and relevant professional institutions 
worldwide. For this article, all articles from a review of mater-
nal GBS colonization [23] were reviewed for inclusion here. In 
addition, we searched reference lists of clinical trials [32, 33], 
and related systematic reviews [21, 34, 35] (Supplementary 
Table 1). There were no date or language restrictions. Articles 
were screened by 2 authors (N. R.  and C. O.), both of whom 
independently assessed the studies for quality and risk of bias, 
and a third author’s opinion (A. S.) was requested in cases of 
differences of opinion.
Articles were included if they described a cohort of preg-
nant women with vaginal or rectovaginal GBS colonization, 
including newborn disease outcomes, and described use 
of IAP, including the proportion of pregnant women who 
received it (if any policy). Studies where women were not sys-
tematically screened for GBS colonization, but were provided 
with IAP based on clinical risk factors with unknown GBS 
colonization status, were not included. To reduce selection 
bias in studies with very small cohorts of pregnant women 
colonized with GBS, which could overestimate the risk of 
GBS disease through preferential reporting, articles were 
included if they reported outcomes from at least 200 pregnant 
women colonized with GBS. This was based on the 1%–2% 
risk of EOGBS previously reported, and the estimated num-
ber of women among whom there would be expected to be at 
least 1 case [1].
Studies were assessed for potential bias as reported in 
Supplementary Table 2. Articles were excluded if there was evi-
dence of recruitment bias, such as studies where rectovaginal 
sampling was in response to clinical risk (which may overesti-
mate disease risk) [19, 21].
We used random-effects meta-analyses to estimate the risk 
of EOGBS using the DerSimonian and Laird method [36]. We 
examined the relationship between IAP coverage and risk of 
EOGBS with linear regression.
Sensitivity analyses were done to explore bias in studies that 
did not include reporting on clinical risk factors for EOGBS. 
These analyses included:
1. Excluding studies that did not report presence or absence of 
any clinical risk factors;
2. Excluding studies without information on gestational age;
3. Excluding studies without reporting of PROM;
4. Excluding studies without reporting of maternal fever.
These sensitivity analyses were applied to studies regardless of 
IAP policy and then to those with and without IAP for GBS 
colonization separately.
RESULTS
Study Selection
From a total of 6128 articles identified through the search 
on maternal colonization [23] and references lists of relevant 
reviews, we identified 30 articles that met the inclusion crite-
ria, 14 of which included cohorts of pregnant women without 
a policy of providing IAP to all women with GBS colonization 
(Figure 2).
Study Characteristics
The majority of studies were observational (25/30), with 5 
of 30 randomized controlled trials (of IAP or vaginal chlor-
hexidine aiming to reduce neonatal sepsis). Eligible articles 
included 20 328 pregnant women colonized with GBS and 101 
cases of EOGBS. Nine articles were from North America and 
15 were from Europe, with 3 studies from Asia and 3 studies 
from Africa (The Gambia, Kenya, and South Africa; Figure 3). 
(See Supplementary Table 3 for study characteristics.) Of the 
included studies, 7 of 30 did not report the prevalence of clinical 
risk factors for EOGBS at delivery, and could therefore be sub-
ject to bias. Among studies reporting the prevalence of clinical 
risk factors, the prevalence of prolonged rupture of membranes 
(defined by most studies as >18 hours, one study as >24 hours) 
was 8% (9 studies), maternal fever (≥38.0°C) was 3% (6 studies), 
and prematurity (<37 weeks) was 5% (11 studies). A number 
of studies did not directly report on risk factors but reported 
proxy measures such as median birth weights (as a proxy for 
gestation).
Outputs From Meta-analyses and Linear Regression
In settings without a policy of providing IAP for GBS coloniza-
tion, the risk of EOGBS in newborns of GBS colonized mothers 
was 1.1% (95% confidence interval [CI], .6%–1.5%) (Figure 3). 
Among the studies in this review where there was a policy of 
providing IAP for GBS colonization (including women who 
received IAP, as well those who missed IAP), the overall risk of 
EOGBS was much lower (0.03% [95% CI, 0–.07%]; Table 1 and 
Supplementary Figure  1), with a mean IAP coverage of 75%. 
When all studies were included, regardless of IAP policy, with 
increasing IAP coverage the risk of EOGBS decreased. Figure 4 
shows IAP coverage against risk of EOGBS. This graph (linear 
regression line) can be used to estimate the risk of EOGBS based 
on different estimates of IAP coverage. Table 2 shows the var-
ying expected risk of EOGBS with different coverage levels of 
IAP based on the linear association. For example, with coverage 
of IAP of 80%, the risk of EOGBS would be expected to be 0.3% 
(95% CI, 0–0.9%). Note that where “no coverage” is reported, 
this does not imply no antibiotics during labor, as antibiotics 
may have been administered for other indications.
In the context of a policy of IAP for GBS colonization, studies 
did not consistently report the timing of administration of IAP, 
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so analysis of the varying risk of invasive disease with the timing 
of the first antibiotic dose before delivery was not possible [37]).
Multiple sensitivity analyses were done to explore poten-
tial bias from the lack of reporting of clinical risk factors for 
EOGBS. These were as follows:
Excluding Studies That Did Not Report Presence or Absence of Any 
Clinical Risk Factors
The risk of EOGBS did not differ significantly between stud-
ies that reported risk factors and those that did not, as shown 
by overlapping confidence intervals (Supplementary Table  4). 
Excluding studies that did not report any risk factor, the risk of 
EOGBS without IAP for GBS colonization was 0.9% (95% CI, 
.4%–1.4%). Including all studies regardless of IAP policy, over-
all risk was also not significantly different (0.3 [95% CI, .1–.4] in 
all vs 0.3 [95% CI, .1–.5] if reporting a risk factor).
Excluding Studies Without Information on Gestational Age
The risk without IAP for GBS colonization among studies 
reporting gestational age of newborns was 0.9 (95% CI, .2–1.5).
Excluding Studies Without Reporting of Prolonged Rupture of Membranes
The risk without IAP for GBS colonization among studies 
reporting prevalence of PROM was 0.8 (95% CI, .5–1.5).
Excluding Studies Without Reporting of Maternal Fever
The risk without IAP for GBS colonization among studies 
reporting maternal fever was comparable to the primary analy-
sis (1.4 [95% CI, .4–2.3]).
The outputs of these analyses, as well as the same analyses 
but including studies with IAP policies, and all studies, are 
summarized in Supplementary Table  4 and Supplementary 
Figures 2–6). These outputs were also comparable to the pri-
mary analysis.
DISCUSSION
The risk of EOGBS was 1.1% (95% CI, .7%–1.6%) for newborns 
born to women colonized with GBS in pregnancy without a 
policy of providing IAP for positive GBS screening. As IAP 
coverage increased the risk of EOGBS decreased, with a linear 
Figure 2. Data search and included studies for risk of early-onset neonatal invasive group B streptococcal disease in the presence of maternal colonization.
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relationship. This clear association allows assessment of risk of 
EOGBS in a population of GBS-colonized pregnant women, 
based on expected coverage of IAP.
This is the most comprehensive review to date of the risk of 
EOGBS disease in newborns born to pregnant women colonized 
with GBS. These results are consistent with previous studies [1, 
38–41], but provide more robust estimates of the risk of EOGBS 
among pregnant women colonized with GBS and, importantly, 
how this varies with and without IAP. The inclusion of data from 
both high- and low-income contexts means the estimated risks 
are generalizable, and support estimates modeling disease burden 
where there are different IAP policies and coverage of IAP [27].
Some studies could have been biased because risk factors for 
EOGBS (prematurity, prolonged rupture of membranes ≥18 
hours and maternal fever ≥38.0°C) were not reported. However 
in the case of prematurity, one of the most important risk factors 
for EOGBS [21], sensitivity analyses did not provide any evidence 
that the risk of EOGBS when including studies reporting gesta-
tional age differed from the primary analysis (0.9% [95% CI, .2%–
1.5%] vs 1.1% [95% CI, .6%–1.5%]). Nevertheless, the prevalence 
of prematurity of 5% among the studies which reported propor-
tion of preterm births, compared to a global estimate of preterm 
birth of 11.1% [42], suggested that preterm newborns may have 
been under-represented. In addition, most preterm neonates 
included were late preterm (35–36 weeks) or moderate preterm 
(≥32 weeks), because swabs for GBS screening are not routinely 
collected before 35 weeks’ gestation, creating a moderate selec-
tion bias. As most (84%) preterm deliveries occur after 32 weeks 
[43], and the majority of EOGBS occur in term newborns [18, 
44–47], the degree of bias is likely to be modest. Underestimation 
of risk may also occur due to misclassification of the exposure. 
Maternal GBS colonization varies during pregnancy, and women 
detected as GBS colonized very early in pregnancy may no longer 
be colonized at delivery, but their newborns would be included as 
exposed, lowering the overall risk estimate.
Other known clinical risk factors for EOGBS disease, pro-
longed rupture of membranes (≥18 hours) or maternal fever 
(>38°C), were not frequently reported. However, the prevalence 
Figure 3. Meta-analysis of risk of early-onset disease without intrapartum antibiotic prophylaxis for group B Streptococcus (GBS) colonization. (Including 6649 GBS-
colonized pregnant women and 85 early-onset GBS cases.) Abbreviations: CI, confidence interval; EOGBS, early-onset group B Streptococcus; ES, estimate; GBS, group B 
Streptococcus.
Table  1. Summary of Risk of Early-Onset Group B Streptococcus by 
Intrapartum Antibiotic Prophylaxis Policya
IAP Policy
No. of GBS- 
Colonized 
Mothers
No. of Early- 
Onset GBS 
Cases Pooled Estimates (Worldwide)
No IAP policy 6649 85 1.1 (95% CI, .6–1.5)
IAP policyb 
(varying 
coverage)
13 348 16 0.03 (95% CI, 0–.07)
Abbreviations: CI, confidence interval; GBS, group B Streptococcus; IAP, intrapartum anti-
biotic prophylaxis.
aSee Meta-analyses in the Supplementary Materials.
bNot including randomized controlled trials.
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of both of these risk factors seems low [48, 49], and in many 
study settings fever was likely to result in antibiotic treatment. 
Both of these factors would likely lead to underestimation of the 
risk of EOGBS disease.
Significant underestimation of risk may also have been 
through inadequate case ascertainment, which is limited by the 
sensitivity of blood cultures. Furthermore, use of IAP may steri-
lize blood cultures without reducing clinical disease to the same 
extent. Indeed “probable” cases of EOGBS, where clinical signs 
of sepsis are associated with GBS colonization in newborns 
without other positive bacteriology, may represent a much 
higher incidence of disease than that based on positive blood 
cultures alone [50, 51]. Such cases are difficult to quantify, how-
ever, and were not included in this review. Case ascertainment 
is also reduced if newborns are not adequately followed up for 
the full 0- to 6-day early-onset period, but as the majority of 
EOGBS cases occur in the first 24 hours after birth, this reduces 
the possible underestimation [28].
Although less likely, overestimation is possible, as the majority 
of studies included were in hospital settings and could select for a 
higher risk group of women. Another source of overestimation, 
but applying only to a minority of studies (4 studies) included, 
was the use of insensitive microbiological methods (lack of selec-
tive enrichment) to detect GBS maternal colonization. This could 
overrepresent women with high density of GBS colonization, and 
thus increased risk of vertical transmission to their newborns [21].
There are likely other factors modifying the risk of EOGBS in 
the presence of maternal GBS colonization, leading to chang-
ing risk in different settings. These could be genetic, especially 
relating to ethnicity, but this was insufficiently described to per-
mit further analyses. Serotypes and sequence type clonal com-
plexes colonizing mothers may also be important, but sufficient 
paired data linking maternal colonizing serotypes with new-
born invasive disease were not available to estimate any varying 
risk. Comorbidities may also be important; recent studies have 
suggested a higher risk of GBS disease in human immunodefi-
ciency virus (HIV)–exposed as well as HIV-infected newborns 
(despite similar colonization prevalence), although this appears 
to have a greater effect on late-onset disease [46, 52].
This review included studies from 4 continents, but the 
majority of studies were from high-income contexts (United 
States or Europe). Applying a risk from high-income contexts to 
low- and middle-income contexts, where access to hospital care 
is limited, may underestimate disease as there may not be anti-
biotic treatment available, even in cases of clinically suspected 
maternal sepsis. There are other factors that may vary across 
settings, such as the proportion of births by elective cesarean 
delivery. Although emergency cesarean delivery in labor after 
ruptured membranes may not significantly change the risk of 
EOGBS with a GBS-colonized mother (risk will vary and may 
be higher depending on the indications for the procedure [53]), 
elective cesarean delivery before the onset of labor or rupture of 
membranes is associated with a much lower risk of EOGBS [54], 
which was not possible to quantify in this review. Therefore, set-
tings with high rates of elective cesarean delivery before labor 
may have a lower risk of EOGBS than described here.
Importantly, this review should not be interpreted as imply-
ing no risk of EOGBS disease in newborns of pregnant women 
who test negative for GBS, as there may be false-negative results, 
and women may become colonized after screening and before 
delivery. In the context of high coverage of microbiological 
screening and IAP, a significant proportion of newborns with 
EOGBS disease are born to pregnant women who tested nega-
tive (or were not tested) for GBS colonization [41, 55].
Table  2. Relationship Between Coverage of Intrapartum Antibiotic 
Prophylaxis and Risk of Invasive Early-Onset Group B Streptococcal (GBS) 
Disease From Cohorts of GBS-Positive Mothers From Linear Regression 
Model
Setting
Estimated 
Coverage
Risk  
(95% CI)
Risk Reduction  
(95% CI)
High coverage of 
microbiological 
screening-based 
policy (eg, US)
80%a 0.3% (0–.9%) 79.2% (45.5%–113%)
Microbiological 
screening-based 
policy with limited 
implementation
40% 0.9% (.4%–1.5%) 40% (6%–73%)
Risk-based strategy 
with high imple-
mentation, and ad 
hoc screening
60%b 0.6% (.1%–1.2%) 59% (26%–93%)
Risk-based strat-
egy with high 
implementation
50%b 0.8% (.3%–1.3%) 50% (16%–83%)
Abbreviations: CI, confidence interval; US, United States.
aBased on US data on estimated coverage of GBS-positive pregnant women with screen-
ing and intrapartum antibiotic prophylaxis [56]
bTheoretical estimated coverages based on data that approximately 40% (or more) of new-
borns with early onset are born to pregnant women with no risk factors [19].
Figure 4. Risk of early-onset disease with varying intrapartum antibiotic proph-
ylaxis coverage of group B Streptococcus (GBS)–colonized pregnant women. 
(Including 20 328 GBS-positive pregnant women and 101 early-onset GBS cases.) 
Abbreviations: CI, confidence interval; IAP, intrapartum antibiotic prophylaxis.
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Overall, our study shows the risk of EOGBS disease in GBS 
colonized pregnant women is at least 1 in 100, which is reduced 
with increasing IAP coverage based on microbiological screen-
ing. The risk is likely underestimated and will lead to a con-
servative minimum estimate of the burden of GBS disease in 
newborns in a compartmental model (Table 3).
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